Current Report Filing (8-k)
October 26 2017 - 7:36AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 26, 2017
(Date of earliest event reported)
ABIOMED, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
Delaware
|
|
04-2743260
|
(State or other Jurisdiction
of Incorporation)
|
|
(IRS Employer
Identification Number)
|
001-09585
(Commission File Number)
22 Cherry Hill Drive
Danvers, MA 01923
(Address of Principal Executive Offices, including Zip Code)
(978)
646-1400
(Registrants Telephone Number, including Area Code)
Not Applicable
(Former
Name or Former Address, if Changed Since Last Report)
Check the appropriate box below
if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c)
|
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On October 26, 2017, we issued a press release reporting our financial results for our second quarter ended September 30, 2017. A copy of the press
release is set forth as Exhibit 99.1 and is incorporated herein by reference. The information contained in this report shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject
to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Securities Act of 1934, whether made before or after the date hereof and regardless of any general
incorporation language in such filing, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements
and Exhibits.
(d)
Exhibits.
Exhibit Index
|
|
|
Exhibit Number
|
|
Description
|
|
|
99.1
|
|
Press release dated October 26, 2017.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.
|
|
|
Abiomed, Inc.
|
|
|
By:
|
|
/s/ Ian W. McLeod
|
|
|
Ian W. McLeod
|
|
|
Vice President and Corporate Controller
|
|
|
(Interim Principal Accounting and Financial Officer)
|
Date: October 26, 2017
ABIOMED (NASDAQ:ABMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
ABIOMED (NASDAQ:ABMD)
Historical Stock Chart
From Apr 2023 to Apr 2024